Table 2.

Summary of research articles published using Gene electrotransfer (GET) alone or in combination with Electrochemotherapy (ECT), or other strategies for treating spontaneous tumors in canine patients. The reported species of the genes used is included in brackets.

Year	Technique	Plasmid	Pulse Parameters	Results	Author
2008	GET	IL-12 (human)	1 × 600 V/cm 100 µs + 4 × 80 V/cm 100 ms	Safety n = 6	Pavlin [84]
2008	ECT + GET	IL-12	2 × 450 V/cm 25 ms	CR: 100% n = 2 An untreated part of a lesion responded	Cutrera [85]
2010	ECT + GET	IL-12 (feline)	2 × 400 V/cm 20 ms	CR: 80% PR: 20% n = 5	Reed [86]
2011	GET + standard therapy	IL-12 (human)	1 × 1200 V/cm 100 µs + 8 × 140 V/cm 50 ms	CR: 36.4% n = 8 (11 tumors)	Pavlin [87]
2011	GET + standard therapy	IL-12 (human)	1 × 600 V/cm 100 µs + 4 × 80 V/cm 100 ms	CR: 33% n = 6	Cemazar [88]
2015	ECT + GET	IL-12 (canine)	2 × 350 V/cm 20 ms	CR: 14% PR: 36% n = 13	Cutrera [89]
2016	ECT + GET	IL-2 (canine) + IL-12 (canine)	ECT 8 × 1000 V/cm 100 µs GET 1 × 1000 V/cm + 4 × 140 V/cm 100 ms (with hyaluronidase pretreatment)	SD: 100% One systemic response n = 5	Maglietti [90]
2017	GET	IL-12 (human)	2 × 750 V/cm 50 µs + 8 × 183 V/cm 10 ms	Authors describe immunostimulatory effects. n = 9	Cicchelero [91]
2017	ECT + GET	IL-12 (human)	ECT: 8 × 1300 V/cm 100 µs GET: 1 × 1200 V/cm 100 µs + 1 × 140 V/cm 400 ms	CR: 72% n = 18	Cemazar [92]
2017	GET + ciclophosphamide	IL-12 (human)	2 × 750 V/cm 50 µs + 8 × 183 V/cm 10 ms	PD Slower tumor growth and improved well-being n = 6	Cicchelero [93]
2017	ECT + GET	IL-12 (human)	ECT: 8 × 1300 V/cm 100 µs GET: 1 × 1200 V/cm 100 µs + 1 × 140 V/cm 400 ms	Reduced neoplastic cell proliferation and induced cellular response. n = 11	Salvadori [94]
2019	ECT + GET + Surgery	IL-12 (canine)	ECT 8 × 1300 V/cm 100 µs GET 2 × 60 V/cm 150 ms	OR: 67% n = 9	Milevoj [95]
2020	GET + various treatments	IL-12	not reported	OR: 82% n = 44	Milevoj [96]